NCT03525392View on ClinicalTrials.gov

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

PHASE1TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 3, 2018

Primary Completion Date

April 3, 2020

Study Completion Date

April 28, 2021

Conditions
Pancreatic Ductal AdenocarcinomaColorectal CancerGastric CancerSquamous Cell Carcinoma of the Head and NeckBone CancerAdvanced CancerRecurrent DiseaseMetastatic Tumours
Interventions
DRUG

177Lu-3BP-227 (also called 177Lu-IPN01087)

The cumulative activity of the treatment investigational medicinal product (IMP) formulation will be administered in two intravenous (i.v.) infusions separated by at least 4 weeks (28 days). Up to 6 administrations can be given (2 cycles plus 4 optional additional)

Trial Locations (8)

1000

Institut Jules Bordet, Brussels

8091

Universitäts Spital Zürich, Zurich

9713

University Medical Center Groningen, Groningen

13385

CHU Timone, Marseille

77030

The University of Texas MD Anderson Cancer Center, Houston

Unknown

Centre Léon Bérard, Lyon

CHU Hôtel Dieu, Nantes

CHU Vaudois, Lausanne

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT03525392 - Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | Biotech Hunter | Biotech Hunter